Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic Non-squamous NSCLC with KRAS G12C Mutation (KRYSTAL-4)

Active:	Yes
Cancer Type:	Lung Cancer	NCT ID:	NCT06875310
Trial Phases:	Phase III	Protocol IDs:	CA239-0004 (primary)
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Bristol-Myers Squibb
NCI Full Details:	https://clinicaltrials.gov/study/NCT06875310

Summary

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation

Objectives

Treatment Sites in Georgia

Northwest Georgia Oncology Centers (NGOC) - Cobb Hospital (Marietta)
340 Kennestone Hospital Blvd.
Suite 100
Marietta, GA 30060
770-281-5101

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.